Physician profile
Thomas Lo Russo
NPI 1710989041
$1,449.94
in general payments reported to CMS, 2019-2025
19 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $20.79 · 2021: $41.98 · 2022: $82.06 · 2023: $252 · 2024: $358 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $249.84 | 2023-2024 | Inspire |
| Glaxosmithkline, LLC. | $160.72 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $134.17 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $131.41 | 2019-2024 | Airsupra, Breztri |
| Genentech USA, INC. | $125.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $64.32 | 2019-2025 | |
| Electromed, INC. | $63.17 | 2022-2024 | Smartvest |
| Harmony Biosciences LLC | $58.42 | 2024 | |
| Amgen INC. | $56.72 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $54.92 | 2024 | Lumryz |
| Mylan Specialty L.P. | $45.38 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $39.88 | 2019 | |
| Philips North America LLC | $39.44 | 2019 | |
| Lilly USA, LLC | $25.50 | 2025 | Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $25.15 | 2025 | Arikayce |
| Grifols USA, LLC | $20.79 | 2020 | |
| Optinose US, INC. | $15.92 | 2024 | |
| Itamar Medical INC | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lo Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.